UPDATE 2-Athersys stroke treatment fails study, shares slide

April 17, 2015 2:25 PM

3 0

* Shares fall as much as 59 pct to $0.90 (Adds details, comments from company and analyst; updates shares)

April 17 (Reuters) - Athersys Inc's stem-cell therapy, its only product to reach human trials, failed a mid-stage study testing it as a treatment for a type of stroke, wiping off more than 40 percent of the company's market value.

Also read: Synergy Pharma's irritable bowel drug succeeds in key study

Read more

To category page

Loading...